Chronic urticaria
Drug research and approvals for chronic urticaria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 34 studies of chronic urticaria are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 34
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- A Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria…NCT07930572 · Phase 1 / Phase 2 · Novelty Nobility, Inc. · starts Oct 15, 2026
- Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to…NCT07833696 · Not reported · Centre Hospitalier Universitaire de Besancon · starts Jan 1, 2020
- Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous…NCT07816328 · Phase 3 · Novartis Pharmaceuticals · starts Sep 21, 2026
- A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)NCT07766499 · Phase 2 · Calixis Inc. · starts Sep 15, 2026
- Mediterranean and Low-Histamine Diets for Pediatric Chronic Spontaneous UrticariaNCT07765979 · Not applicable · Saglik Bilimleri Universitesi · starts Nov 23, 2025
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity…NCT07717905 · Phase 1 / Phase 2 · Bambusa Therapeutics · starts Jun 29, 2026
- Trial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain.NCT07652944 · Not applicable · Joe X. Zhang · starts Jul 1, 2026
- Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)NCT07642557 · Not reported · Novartis Pharmaceuticals · starts Aug 4, 2026
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of…NCT07540910 · Phase 1 · Enanta Pharmaceuticals, Inc · starts Apr 1, 2026
Phase 3 8
- OmalizumabIg epsilon chain C region inhibitor
- LigelizumabIg epsilon chain C region inhibitor
- Remibrutinib
- Barzolvolimab
- DupilumabInterleukin-4 receptor subunit alpha antagonist
- HistamineHistamine H1 receptor agonist
- DiphenhydramineHistamine H1 receptor antagonist
- LevocetirizineHistamine H1 receptor antagonist
Phase 2 10
- EtanerceptTNF-alpha inhibitor
- CanakinumabInterleukin-1 beta inhibitor
- TirabrutinibTyrosine-protein kinase BTK inhibitor
- AZD1981G protein-coupled receptor 44 antagonist
- BenralizumabInterleukin-5 receptor subunit alpha inhibitor
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- TezepelumabThymic stromal lymphopoietin inhibitor
- RilzabrutinibTyrosine-protein kinase BTK inhibitor
- LirentelimabSialic acid-binding Ig-like lectin 8 inhibitor
- Ucenprubart
Phase 1 or earlier 2
- BriquilimabStem cell growth factor receptor inhibitor
- MepolizumabInterleukin-5 inhibitor
How its trials ended
167 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 51 whose ending is known, 55% met their primary endpoint, 0% missed it and 45% stopped early.
- Completed, result not reported6740%
- Ongoing3018%
- Met its primary endpoint2817%
- Status unknown1911%
- Stopped: other or unclear117%
- Stopped: sponsor or business decision53%
- Stopped: enrollment or feasibility42%
- Stopped: lack of efficacy21%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA